| Autor: |
Peng-Wei, Luo, Liang, Wang, Wen-Feng, Cao, Sha-Dan, Li, Xiao-Ke, Huang, Ji-Wen, Liu, You-Guang, Zhao, Ting-Ting, Zhou, Shi-Wei, Yang, Shi-Yuan, Qin |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Zhonghua nan ke xue = National journal of andrology. 25(1) |
| ISSN: |
1009-3591 |
| Popis: |
To investigate the long-term clinical value of prostate 125I brachytherapy (BT) combined with maximal androgen blockade (MAB) in the treatment of metastatic prostate cancer (mPCa).We retrospectively analyzed the clinical data on 173 cases of mPCa treated by MAB (n = 126) or BT+MAB (n = 47) from December 2011 to December 2016 and followed up for 6－76 (44.17 ± 19.73) months. We compared the PSA level, prostate volume, IPSS, progression-free survival, and the rates of 3- and 5-year overall survival between the two groups.After treatment, the minimum PSA level was significantly lower in the BT+MAB than in the MAB group ［3.77 ± 4.14］ vs ［5.96 ± 7.01］ ng/ml, P = 0.046) and the time to reach the minimum level was shorter in the former than in the latter (［5.19 ± 2.83］ vs ［6.52 ± 3.34］ mo, P = 0.016). The prostate volume was markedly reduced in both of the groups at 1, 3 and 5 years after treatment as compared with the baseline, even more significantly in the BT+MAB than in the MAB group (P0.01), though with no statistically significant difference between the two groups before treatment (P = 0.307). The IPSS was remarkably decreased in both of the groups at 1 and 3 years (P0.01) but showed no significant difference at 5 years after treatment as compared with the baseline (P0.05) or between the two groups before and after treatment (P0.05). The progression-free survival was obviously longer in the BT+MAB than in the MAB group (［37.29 ± 15.73］ vs ［29.41 ± 14.37］ mo, P = 0.011), and the rates of 3- and 5-year overall survival were higher in the former than in the latter (74.60% and 60.70% vs 62.60% and 51.50%, P = 0.227 and P = 0.356). Kaplan-Meier survival curves showed no statistically significant difference in the overall survival between the two groups (P = 0.105).Both MAB and BT+MAB are effective therapies for mPCa, but the latter can achieve a longer progression-free survival. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
